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Reduced IFNl4 activity is associated with
improved HCV clearance and reduced expression
of interferon-stimulated genes
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Hepatitis C virus (HCV) infections are the major cause of chronic liver disease, cirrhosis and
hepatocellular carcinoma worldwide. Both spontaneous and treatment-induced clearance of
HCV depend on genetic variation within the interferon-lambda locus, but until now no clear
causal relationship has been established. Here we demonstrate that an amino-acid
substitution in the IFNl4 protein changing a proline at position 70 to a serine (P70S)
substantially alters its antiviral activity. Patients harbouring the impaired IFNl4-S70 variant
display lower interferon-stimulated gene (ISG) expression levels, better treatment response
rates and better spontaneous clearance rates, compared with patients coding for the fully
active IFNl4-P70 variant. Altogether, these data provide evidence supporting a role for the
active IFNl4 protein as the driver of high hepatic ISG expression as well as the cause of poor
HCV clearance.
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H
epatitis C virus (HCV) infections are the major cause of
chronic liver disease, cirrhosis and hepatocellular carci-
noma worldwide1. HCV is parenterally transmitted,
mainly due to injection drug use, unsafe transfusions and
therapeutic injections. In 70–80% of those infected, the virus
persists and the infection becomes chronic, and eventually
requires antiviral therapy. During the past 25 years,
recombinant interferon-alpha (IFNa) has been an essential
component of HCV treatment2, however, the recent availability
of potent direct-acting antiviral agents (DAA) is changing the
therapeutic options.
The overall sustained virological response (SVR) rate achieved
using a combination of pegylated IFNa (pegIFNa) and ribavirin
is only about 50%, and the prognosis for individual patients
strongly depends on their genetic background. In particular, the
genetic variation within the IFNL3 (IL28B) locus is crucial in
determining the treatment outcome3–6. Furthermore, the
response to IFN-based therapy depends strongly on the
expression of IFN-stimulated genes (ISGs) in patients before
the initiation of treatment7–9 and variations near the IFNL3
(IL28B) locus correlate with the ISG induction in the liver10–12.
Somewhat paradoxically, patients showing increased
pretreatment expression of ISG in the liver respond poorly to
pegIFNa/ribavirin therapy7–9. However, the mechanism
responsible for driving ISG induction in the HCV-infected liver
has remained elusive. Roughly, a quarter of HCV-infected
individuals clear the virus spontaneously, this largely happens
during the acute phase of the infection. Somewhat surprisingly,
the genetic variations near the IFNL3 (IL28B) locus are also
strongly associated with spontaneous clearance of HCV
infection13,14. That points towards a pivotal role for IFNls in
HCV clearance and a possible inﬂuence of IFNls on the adaptive
immune response that is generated during the acute phase of
HCV infection.
A recent key discovery identiﬁed the IFNL4 gene and showed
that a polymorphism (rs368234815), which causes the disrup-
tion of the IFNL4 reading frame, correlates with a substantially
better treatment response15,16 as well as better spontaneous
clearance rate13. Thus, patients having a nonfunctional IFNL4
gene are more likely to clear the HCV infection. This suggests
that the production of IFNl4 in carriers of the ancestral
rs368234815 DG allele is responsible for the transcriptional
activation of ISGs, thus providing a molecular link between the
genotype and clearance of HCV. This hypothesis is supported by
the recent ﬁnding that recombinant IFNl4 protein strongly
stimulates Jak-STAT signalling and ISG induction through
binding to the IFNl receptor17. Here we describe a strong link
between a reduced antiviral activity of the IFNl4 protein and a
reduced hepatic ISG expression as well as an improved HCV
clearance.
Results
Substitution at position 70 impairs the activity of IFNk4. Three
non-synonymous single-nucleotide polymorphisms (SNPs) in the
IFNL4 gene were previously described but not characterized15,18,
those being C17Y (rs73555604), R60P (rs142981501) and P70S
(rs117648444). We noted that a P70S substitution (rs117648444)
could potentially alter the activity of the protein, in addition this
has a minor allele frequency (MAF) in Caucasian of 0.11
(HapMap), whereas the two other have 0 and 0.025, respectively.
Proline 70 is located outside of the assumed receptor
binding site19,20, but structural modelling suggests that P70 is
important for the stability of the IFNl4 protein17. In the
following, the two variants of IFNl4 will be denoted as
IFNl4-P70 and IFNl4-S70, respectively.
We expressed the mature form of both variants in Escherichia
coli, puriﬁed them (Fig. 1a) and tested their activity. The IFNl4-
S70 variant induced signiﬁcantly lower levels of both MX1 and
IFIT1 transcription in human hepatocellular carcinoma cells
(HepG2; Fig. 1b). Next, a dose–response experiment was
performed in human embryonic kidney cells (HEK293) trans-
fected with an IFN-responsive ﬁreﬂy luciferase reporter construct,
a Renilla luciferase construct for normalization and a construct
expressing the IFNlR1 receptor chain (Fig. 1c). We obtained
half-maximal effective concentration (EC50) values of
4.0 ngml 1 for IFNl4-P70 and 9.5 ngml 1 for IFNl4-S70.
This difference was signiﬁcant using 99% conﬁdence intervals
(Supplementary Table 1). Finally, we performed an antiviral assay
using encephalomyocarditis virus (EMCV) infection in HepG2
cells (Fig. 1d; Supplementary Table 1). Here we saw a signiﬁcant
shift in the (EC50) values from 0.2 ngml 1 for the IFNl4-P70 to
1.4 ngml 1 for IFNl4-S70. Thus, the IFNl4-S70 variant is
substantially less active than the IFNl4-P70 variant.
rs117648444A is an independent predictor of HCV clearance. If
the active IFNl4 protein is the causative agent responsible for the
poor HCV clearance in patients, then one would expect the P70S
substitution (rs117648444) to inﬂuence the ability of patients to
clear HCV. Thus, we evaluated the role of the rs117648444A
(IFNl4-S70, MAF¼ 0.11) and rs368234815DG (expressing IFNl4,
MAF¼ 0.35) polymorphisms in HCV clearance in a cohort of
574 chronically infected patients who underwent pegIFNa/riba-
virin treatment, as well as in 122 patients with spontaneous
clearance (Table 1; Supplementary Tables 2 and 3). We analysed
the independent contribution of each polymorphism, by includ-
ing both of them in the same logistic regression model. As
expected, rs368234815DG was associated with a lower SVR rate
(odds ratio (OR)¼ 0.23, 95% conﬁdence interval (CI) 0.15–0.35,
P¼ 1.5E-11, dominant mode of inheritance), while rs117648444A
(IFNl4-S70) was associated with a higher SVR rate (OR¼ 1.66,
95% CI 1.08–2.55, P¼ 0.02). Thus, both rs117648444A and
rs368234815DG are independent predictors of treatment-induced
HCV clearance. A similar trend was observed for spontaneous
clearance (OR¼ 0.21, 95% CI 0.13–0.34, P¼ 4.4E-10 for
rs368234815DG; OR¼ 1.63, 95% CI 0.88–3.02, P¼ 0.12 for
rs117648444A; Table 1).
Stratiﬁcation of patients according to IFNk4 functionality.
A haplotype analysis was performed to understand the
co-inheritance pattern of rs368234815 and rs117648444, which
would help to clarify the role of the activity of IFNl4 in HCV
clearance. This analysis showed that 95% of the chromosomes are
composed of three main haplotypes: TT G (65%), which is pre-
dicted not to produce IFNl4, DG G (22%), which is predicted to
produce the IFNl4-P70 variant, and DG A, which is predicted to
express the IFNl4-S70 variant (11%; Supplementary Table 4).
The frequency distribution in our study population is in accor-
dance with previously published data15,18. The fourth haplotype
TT A, which does not express IFNl4, was found in only 0.5% of
the chromosomes, and is grouped with the TT G haplotype in the
subsequent analyses. The DG G haplotype (IFNl4-P70,
R2¼ 0.74) was in linkage disequilibrium (LD) with the SNP
rs8099917, which emerged as the top hit for spontaneous or
treatment-induced HCV clearance in three out of four initial
hepatitis C genome-wide association studies (GWAS; Table 2).
The haplotypic combinations produced eight diplotypes
(Table 3), which can be classiﬁed into three main functional
groups according to their ability to produce IFNl4-P70 or
IFNl4-S70. The ﬁrst group consists of patients not producing
IFNl4 (N¼ 283). The second group contains diplotypes that
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exclusively code for IFNl4-S70 (N¼ 114). The third group
consists of those that give rise to the fully functional IFNl4-P70
(N¼ 299). This group is composed of 270 samples with the TT
G/DG G and the DG G/DG G diplotype producing only the
IFNl4-P70 variant, and 29 samples with the DG A/DG G
diplotype producing both variants of IFNl4.
IFNk4-S70 associates with a better clearance rate of HCV. We
analysed the response to treatment in patients producing IFNl4-
S70 alone and those producing IFNl4-P70 alone grouped with
IFNL4-P70/S70 compared with those not producing IFNl4.
Patients not producing IFNl4 had an overall SVR rate of 81% after
treatment with pegIFNa/ribavirin compared with only 47% among
those who produced the IFNl4-P70 or P70/S70 variants
(OR¼ 0.21, 95% CI 0.14–0.33, P¼ 8.3E 13; Table 1; Fig. 2a).
We then excluded patients not producing IFNl4 to speciﬁcally
assess the role of the P70S substitution. Interestingly, patients who
produced exclusively the IFNl4-S70 had a much higher response
rate (69%) compared with those producing the IFNl4-P70 or P70/
S70 variants (OR¼ 2.52, 95% CI 1.55–4.13, P¼ 0.0002). This
clearly shows that the chance of clearing the virus is highest in the
group of patients not expressing IFNl4, slightly lower in those
expressing the impaired IFNl4-S70 variant and the worst in those
expressing the fully active IFNl4-P70 form. The differences in SVR
rates between all three groups were signiﬁcant. This agrees well
with the biochemical data, which show that IFNl4-S70 has an
impaired but still clearly measurable activity. These associations
were still signiﬁcant in a multivariate model after adjustment for
relevant covariates (Table 1). The association was similar, although
less signiﬁcant, when the analysis was restricted to patients infected
with HCV genotype 1 (Supplementary Table 5).
Roughly, a quarter of all HCV-infected individuals sponta-
neously clear the HCV infection, mainly during the acute phase of
the infection by mounting an efﬁcient immune response to the
virus21. We investigated whether the level of IFNl4 activity was
associated with the spontaneous clearance. Similarly to what was
observed for the treatment-induced clearance, the proportion of
patients with spontaneous clearance was 29% among patients
unable to produce IFNl4, 7% among those producing the IFNl4-
P70 or P70/S70 variants and 15% among those producing
exclusively IFNl4-S70 (Table 1; Fig. 2b).
IFNk4-P70 is associated with high ISG expression. We have
previously shown that the quantiﬁcation of the expression of four
ISGs (IFI27, ISG15, RSAD2 and HTATIP2) in liver biopsy sam-
ples allows one to predict the response to pegIFNa/ribavirin
treatment10. This 4-gene classiﬁer was obtained through a
multivariate analysis using decision tree ensembles in the form
of a random forest classiﬁer and is expressed as the probability of
obtaining a sustained virological response (pSVR). The pSVR
value contains the collective information from the four genes
measured and is inversely correlated with ISG expression in the
liver10. In the present work, the 4-gene classiﬁer was used as a
surrogate marker for the overall ISG expression in 104 liver
biopsies from patients with chronic hepatitis C. The biopsies were
then genotyped for the IFNl4 variants and classiﬁed into the
three groups corresponding to the genomic analysis described
above. In an analysis including all viral genotypes, the median
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Figure 1 | Activity of recombinant human IFNk4-P70 and IFNk4-S70 variants. Data represent the results of multiple experiments with similar results.
(a) A coomassie-stained 12% SDS–polyacrylamide gel electrophoresis of the puriﬁed proteins. Cleavage of the N-terminal His-Tag was only partial for
IFNl3, hence the double band. The upper arrow indicates the migration of the IFNl3-His-tag fusion protein; the lower arrow indicates migration of
the mature IFNl3/l4 proteins. (b) HepG2 cells were treated with 1 ngml 1 of IFNl3, IFNl4-P70 or IFNl4-S70. After 4 h, the mRNA levels of the ISGs
IFIT1 and MX1 were quantiﬁed by real-time quantitative PCR. Experiments were performed in quadruplicates; replicates, mean and s.d. are plotted.
The P value for IFNl4-P70 versus IFNl4-S70 is shown (Mann–Whitney test). (c) The activity of IFNl4-S70 was tested and compared with IFNl4-P70 in
HEK293 cells, which were transfected with the pEF2 vector containing IFNlR1, as well as Renilla and ﬁreﬂy luciferase reporters 24 h before IFN treatment.
The ﬁreﬂy construct is IFN inducible, whereas the Renilla construct is constitutively expressed. Dose responses of IFNs were performed in quadruplicates.
Mean and s.d. are shown. (d) HepG2 cells were treated with IFNl4-S70 or IFNl4-P70 for 24 h and subsequently infected with EMCV. Cell survival
was analysed using the conversion of MTT to formazan in living cells by measurement of the A600. Data are presented as a percentage of a non-infected
cell control. Error bars depict s.d. of 10 replicates.
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pSVR was 85% in group 1 (no IFNl4, N¼ 39), 72% in group 2
(functionally defective IFNl4-S70, N¼ 12) and 46% in group 3
(fully functional IFNl4-P70, N¼ 53). The difference between
groups 1 and 3, but not between 1 and 2, was statistically
signiﬁcant (Fig. 3a). The results did not change when the analysis
was restricted to patients infected with HCV genotype 1 (Fig. 3b).
Thus, there is a clear correlation between the activity of the
IFNl4 protein and the hepatic ISG expression level.
Discussion
Because IFNl4-P70, but not the functionally defective IFNl4-
S70, is associated with a strong induction of ISG expression (and
therefore a low pSVR), we conclude that IFNl4 is the major
component of the molecular mechanisms responsible for hepatic
ISG expression in patients with HCV infections. Sustained
signalling through the IFNl receptor can inhibit subsequent
responses to type I IFN through the induction of the USP18
protein22,23. Therefore, prolonged IFNl signalling caused by the
IFNl4 protein is obviously inhibitory to subsequent treatment
with pegIFNa/ribavirin. Interestingly, previous work has
observed an association between both SNP rs12979860 (ref. 14)
(situated in the IFNL4 intronic region) and rs368234815 (ref. 13)
(the DG allele determining IFNl4 expression) and the rate of
spontaneous clearance of HCV. We observed a clear correlation
between the activity of IFNl4 and the spontaneous clearance rate.
Patients producing the impaired IFNl4-S70 had a 15% chance of
spontaneous clearance compared with a 7% clearance rate among
Table 1 | Association between IFNL4 rs368234815 and rs117648444 polymorphisms and spontaneous and treatment-induced
HCV clearance.
Response to treatment (N¼ 574) NR SVR Proportion SVR Univariate models Multivariate models*
OR (95% CI) P value OR (95% CI) P value
Individual contribution of both polymorphisms
rs368234815 TT/-G or -G/-G versus TT/TT 0.23 (0.15–0.35) 1.5E 11 0.16 (0.09–0.28) 3.2E 10
rs117648444 G/A or A/A versus G/G 1.66 (1.08–2.55) 0.02 2.35 (1.31–4.26) 0.004
Contribution of IFNl4-S70 alone and IFNl4-P70 alone grouped with IFNl4-P70/S70 compared with that of no IFNl4
No IFNl4 39 161 0.81 Reference Reference
IFNl4-S70 alone 30 67 0.69 0.54 (0.31–0.94) 0.03 0.61 (0.29–1.28) 0.19
IFNl4-P70 and P70/S70 147 130 0.47 0.21 (0.14–0.33) 8.3E 13 0.14 (0.08–0.26) 2.7E-11
Contribution of IFNl4-S70 alone compared with that of IFNl4-P70 alone grouped with IFNl4-P70/S70 (after exclusion of no IFNl4)
IFNl4-S70 alone 30 67 0.69 2.52 (1.55–4.13) 0.0002 4.22 (2.10–8.51) 5.5E-05
IFNl4-P70 and P70/S70 147 130 0.47 Reference Reference
Spontaneous clearance (N¼696) CHI SC Proportion clearance OR (95% CI) P value OR (95% CI) P value
Individual contribution of both polymorphisms
rs368234815 TT/-G or -G/-G versus TT/TT 0.21 (0.13–0.34) 4.4E 10 0.20 (0.12–0.33) 2.4E 10
rs117648444 G/A or A/A versus G/G 1.63 (0.88–3.02) 0.12 1.60 (0.86–3.00) 0.14
Contribution of IFNl4-S70 alone and IFNl4-P70 alone grouped with IFNl4-P70/S70 compared with that of no IFNl4
No IFNl4 200 83 0.29 Reference Reference
IFNl4-S70 alone 97 17 0.15 0.42 (0.24–0.75) 0.003 0.41 (0.23–0.74) 0.003
IFNl4-P70 and P70/S70 277 22 0.07 0.19 (0.12–0.32) 1.3E 10 0.18 (0.11–0.30) 5.0E 11
Contribution of IFNl4-S70 alone compared with that of IFNl4-P70 alone grouped with IFNl4-P70/S70 (after exclusion of no IFNl4)
IFNl4-S70 alone 97 17 0.15 2.21 (1.12–4.33) 0.02 2.27 (1.13–4.54) 0.02
IFNl4-P70 and P70/S70 277 22 0.07 Reference Reference
CI, conﬁdence interval; CHI, chronic infection; NR, non-response to treatment; OR, odds ratio; SC, spontaneous clearance; SVR, sustained virological response.
*Multivariate models for spontaneous clearance are adjusted for age, sex and HCV risk. Multivariate models for response to treatment are adjusted for age, sex, ﬁbrosis stage and viral genotype.
Multivariate models include a smaller number of treated patients (N¼404) due to missing covariates.
Table 2 | Linkage disequilibrium between different IFNL4 polymorphisms.
rs8099917 rs12979860 rs368234815 rs117648444 TT G (no IFNk4) DG G (IFNk
4-P70)
DG A (IFNk
4-S70)
TT A
(no IFNk4)
rs8099917 0.23
rs12979860 0.45 0.37
rs368234815 0.44 0.92 0.35
rs117648444 0.03 0.21 0.19 0.11
TT G (no IFNl4) 0.43 0.93 0.98 0.23 0.65
DG G (IFNl4-P70) 0.74 0.53 0.60 0.04 0.59 0.24
DG A (IFNl4-S70) 0.03 0.21 0.22 0.95 0.22 0.04 0.11
TT A (no IFNl4) 0.00 0.00 0.00 0.04 0.01 0.01 0.00 0.01
IFNl, interferon-lambda.
Off-diagonal elements represent estimates of R2; R24 0.7 are indicated in bold. Diagonal elements represent minor allele frequencies. Single-nucleotide polymorphisms were coded 0, 1 or 2 for the
presence of zero, one or two copies of the minor allele. Haplotypes were coded in a similar way, that is, 0 for the absence of the haplotype, 1 for the presence of one copy of the haplotype and 2 of the
presence of 2 copies of the haplotype.
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patient coding for the active IFNl4-P70 variant. Among patients
homozygous for the rs368234815 TT allele (major allele, causing a
IFNL4 frame shift mutation), the clearance rate was increased to
29%. As the majority of spontaneous clearance occurs during the
acute phase of HCV infection, the IFNl4 protein must inﬂuence
the early phase of an HCV infection in a way that is favouring
development of a chronic infection and thus impairing
spontaneous clearance. We speculate that the IFNl4 protein
can inﬂuence adaptive immunity, which is established during the
acute phase, and that this is a long-lasting inﬂuence. Our data link
the active form of IFNl4 (IFNl4-P70) to high ISG expression
and thus to low level of viral replication, which somewhat
counterintuitively leads to poor treatment response. We suggest
that IFNl4-P70-driven ISG expression causes lower level of viral
Table 3 | IFNL4 haplotype combination and associated clearance phenotypes.
Diplotype* N Proportion of patients IFNk4 production SVR % SVR CHI SC % SC
70P 70S  þ
TT G/TT G 277 0.398   39 156 0.800 195 82 0.296
TT G/DG G 231 0.332 þ  111 105 0.486 216 15 0.065
TT G/DG A 110 0.158  þ 30 64 0.681 94 16 0.146
DG G/DG G 39 0.056 þ  17 17 0.500 34 5 0.128
DG A/DG G 29 0.042 þ þ 19 8 0.296 27 2 0.069
TT G/TT A 5 0.007   0 4 1.000 4 1 0.200
DG A /DG A 4 0.006  þ 0 3 1.000 3 1 0.250
TT A/TT A 1 0.001   0 1 NA 1 0 NA
CHI, chronic infection; IFNl, interferon-lambda; NA, not applicable; SC, spontaneous clearance; SVR, sustained viral response.
*Diplotypes are composed of rs368234815, which can be either TT or DG, and rs117648444, which can be either G or A.
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Figure 2 | Association of IFNL4 rs368234815 and rs117648444 polymorphisms and their diplotypes with treatment-induced and spontaneous HCV
clearance. Patients were divided into three groups based on their diplotype: those predicted not to produce IFNl4, those predicted to produce IFNl4-S70
and those predicted to produce IFNl4-P70. The latter group included 29 patients (*) with a diplotype encoding both IFNl4-P70 and IFNl4-S70. Data
represent the proportion of patients infected with all HCV genotypes, who achieved (a) sustained virological response after treatment with pegIFNa/
ribavirin or (b) spontaneous clearance. P values were obtained by logistic regression. N¼ number of patients in a given group.
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Figure 3 | Association of IFNL4 genotype with ISG expression in liver biopsies. Overall ISG expression in liver biopsies was assessed with the 4-gene
classiﬁer calculating the probability of a sustained virological response for pegIFNa/ribavirin treatments. A high pSVR corresponds to low overall ISGs
expression in the liver and vice versa. The biopsies were grouped according to their IFNL4 diplotype as indicated. Shown are results including (a) all HCV
genotypes or (b) HCV genotype 1 only. Statistical analysis with Kruskal–Wallis revealed signiﬁcant overall differences of the median pSVR of the three
groups for all genotypes and for genotype 1 only, with P¼0.0058 and P¼0.026, respectively. Between groups, only the groups ‘no IFNl4’ and ‘IFNl4 P70’
were signiﬁcantly different from each other (Dunn’s multiple comparison test). N¼ number of samples per group.
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replication, which in turn leads to an inefﬁcient adaptive immune
response, and that this is the base of poor HCV clearance. This is
supported by a recent study showing an association between the
rs368234815 DG allele (IFNl4 expression) and activity level of
T cells24. Furthermore, our ﬁndings are supported by a recent
paper, showing that patients carrying the IFNl4-S70-coding allele
exhibit a faster decline in HCV RNA levels at week 4 of
treatment25.
Combining rs368234815 and rs117648444 polymorphisms, it is
possible to stratify patients into three groups, with the highest
cure rates in patients not producing IFNl4, intermediate cure
rates among those producing the IFNl4-S70 variant and the
lowest cure rates among those producing the IFNl4-P70 variant.
Furthermore, there is an excellent agreement between the
predicted response rate (pSVR) obtained by measuring ISG
expression in liver biopsies and the experientially observed SVR,
once patients are stratiﬁed according to the three groups deﬁned
above. In our cohort, 26% of the patients being able to express
IFNl4 harbour only the IFNl4-S70 variant, and thus have a
prognosis that is almost as good as those not producing IFNl4.
Thus, by combining both polymorphisms, it is possible to
substantially improve the accuracy of the predicted response rate
before treatment. In addition, we can clarify a discrepancy that
has puzzled the ﬁeld. The rs368234815 polymorphism that
determines the ability to express IFNl4 is not in LD with
rs8099917, which was found as a good SVR predictor in three out
of four of the initial GWAS studies3–6. This was unexpected and
did initially argue against the IFNl4 protein as the causative
agent; however, it is now clear that the minor allele of rs8099917
speciﬁcally tags the haplotype producing the IFNl4-P70 variant,
which we have shown to be associated with the poorest clearance
rates.
One may argue that the use of genetic markers may become
obsolete with the advent of direct-acting antiviral agents (DAAs),
due to their high cure rates26–28. Nevertheless, the role of IFNL3/
IFNL4 polymorphisms has been convincingly demonstrated in
the ﬁrst generation DAA treatment regimes. The SOUND-C2
trial assessing the combination of faldaprevir and deleobuvir with
or without ribavirin showed a signiﬁcantly higher SVR rates for
patients homozygous for the favourable allele of rs12979860 (CC),
clearly demonstrating a role for IFNL genotype in IFN-free DAA
treatment regimens29. Thus, in mechanistic term, the role of the
IFNL genotype is not restricted to IFN-based therapies, but do
inﬂuence DAA-based treatments. However, recent development
in DAA combination therapies using drugs with a substantially
improved potency has pushed SVR above 90% for all patients,
regardless of their IFNL genotype. With cure rates, this high
knowledge of the genotype will have little impact on patients’
choices of treatment. However, there are several clinical as well as
scientiﬁc reasons to pursue a deeper understanding of how IFNL
genotype impact viral clearance. Several recent studies show that
rs368234815 inﬂuences the response kinetics to DAA28,30;
however, the role of rs117648444 in DAA treatment has not yet
been investigated. This suggests that patients not expressing
IFNl4 can receive a shortened DAA treatment and possibly also
reduced doses. There will be both obvious beneﬁts for patients
and substantial cost reduction by a targeted shortening of therapy
in patients with favourable IFNL genotype. Our study clearly
shows that the decision should be based on a dual genotyping of
rs117648444 and rs368234815.
The expression of active IFNl4 inﬂuences both IFN-based and
IFN-free treatment of chronic HCV infections, as well as strongly
inﬂuences the spontaneous clearance rate. These observations
point towards a fundamental role of active IFNl4 in facilitating
and maintaining a chronic HCV infection. A recent study showed
that rs368234815 also inﬂuenced susceptibility to cytomegalovirus
retinitis among HIV-infected patients31, suggesting that the
IFNl4 protein might play detrimental role in several different
chronic viral infections. Thus, we believe that the activity of
IFNl4 could play an important role in multiple chronic viral
infections by a mechanism similar to that observed in hepatitis C.
Methods
Protein expression and puriﬁcation. BL21 (DE3) E. coli cells transformed with
the plasmids were grown at 37 C in Luria Bertani medium containing
100 mgml 1 ampicillin and 100 ml antifoam A concentrate (Sigma-Aldrich, cata-
logue number A5633) under continuous shaking until an OD600 of 0.8–1. Protein
expression was induced by adding 1mM isopropyl-b-D-thiogalactopyranoside and
incubating for another 4 h at 37 C. Refolding and puriﬁcation were performed as
previously described32. The His-tag was removed by the tobacco etch virus (TEV)
protease cleavage after the refolding was completed. The TEV was removed during
the subsequent cation exchange chromatography using a HiTrap SP FF column.
The TEV cleavage was omitted for IFNl3. It is worth noting that the yield of
IFNl4 protein is low with 1–2mg of puriﬁed protein from 12 l E. coli culture. We
did not note any consistent differences in the expression levels between IFNl4-P70
and IFNl-S70.
Plasmids. The IFNl4-S70 constructs were generated by site-directed mutagenesis
using PfuUltra II Fusion HS DNA polymerase according to the manufacturer’s
instructions (Agilent). For the mammalian cell expression, pEF2-IFNl4-S70-FLAG
was generated on pEF2-IFNl4-P70-FLAG template using forward 50-CCGCGGAG
AATCCCTCCTGGGGC-30 and reverse 50-GCCCCAGGAGGGATTCTCCGCGG-30
primers. For the expression in E. coli, pET15b-IFNl4-S70 was generated on
pET15b-IFNl4-P70 construct using forward 50-GCTGCTCGGACGAGGCGAAT
CACGACGCGGACG-30 and reverse 50-CGTCCGCGTCGTGATTCGCCTCGTC
CGAGCAGC-30 primers. The following PCR programme was used: (1) 95 C for
30 s; (2) 16 cycles of 95 C for 30 s, 65 C for 1min and 72 C for 4min; and (3)
72 C for 10min.
Cell culture. Unless otherwise stated, all cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM), which was supplemented with 10% fetal bovine serum,
100Uml 1 penicillin and 100 mgml 1 streptomycin. Cells were purchased from
the German Collection of Microorganisms and Cell Cultures, DSMZ (HepG2
DSMZ-No.: ACC-180; HEK293 DSMZ-No.: ACC-305).
Activity assay in HEK293 cells. HEK293 cells were seeded at a density of
7.5 104 cells per well in a 48-well plate and left to rest for 24 h. After 24 h, the cells
were transfected with the pEF2 plasmid encoding IFNlR1, ﬁreﬂy luciferase under
the control of the Mx1 promoter33 and Renilla luciferase under the control of the
b-actin promoter. Eighteen hours post-transfection, cells were induced in
quadruplicates with eight dilutions of IFNl4-P70 and IFNl4-S70 in the
concentration range covering 0.006–100 ngml 1 for 24 h. After 24 h, the cells were
washed with PBS and lysed with Passive Lysis Buffer (Promega). The lysates were
spun down at 10,000 g for 2min at 4 C, and the cleared lysates were used for the
measurement of luciferase activity (Dual-Luciferase Reporter Assay System,
Promega). EC50, efﬁcacy and exponential slope values were estimated in GraphPad
prism version 5.04 by ﬁtting a sigmoidal equation to the plot. The equation used
for ﬁtting was: ﬁreﬂy/Renilla ratio¼ baselineþ (efﬁcacy baseline)/
(1þ 10((logEC50X) Slope)). Values for baseline were restrained to zero.
Real-time quantitative PCR. HepG2 cells were seeded at a density of 2 105 cells
per well in 12-well plates, and after 24 h, fresh media were added with the indicated
IFNs in quadruplicates. After 4 h of incubation, cells were lysed and RNA was
puriﬁed using an extraction kit (Omega) according to the manufacturer’s
instructions. Complementary DNA synthesis was performed with 1 mg RNA using
RevertAid reverse transcriptase and random hexamer primer according to the
manufacturer’s instructions (Thermo Scientiﬁc). The cDNA obtained from cells
was quantiﬁed by real-time quantitative PCR using SYBR Green I (Roche) on
Roche LightCycler 480 II. The following primers were used: GAPDH, forward
50-CGACCACTTTGTCAAGCTCA-30 and reverse 50-GGTGGTCCAGGGGTCTT
ACT-30; IFIT1, forward 50-CCTCCTTGGGTTCGTCTACA-30 and reverse 50-GGC
TGATATCTGGGTGCCTA-30 ; and MX1, forward 50-ACCTACAGCTGGCTCCT
GAA-30 and reverse 50-CGGCTAACGGATAAGCAGAG-30. The cycling para-
meters were: 95 C for 10min followed by 45 cycles of 95 C for 10 s, 60 C for 20 s
and 72 C for 12 s. The crossing points of the ampliﬁcation curves were determined
using the second derivate method on the Roche 480 LightCycler software 1.5
(Roche). The level of mRNA was normalized against the GAPDH mRNA content.
The mean of the quadruplicates of the untreated control was used to calculate the
fold induction for the other samples.
Antiviral assay. HepG2 cells were seeded at a concentration of 1.8 104 cells per
well in 96-well plates and incubated with 20 dilutions of IFNl4-P70 or IFNl4-S70
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in the concentration range covering 0.008–200 ngml 1 for 24 h. The cells were
then infected with EMCV (VR-129B strain) at a multiplicity of infection of 0.45.
After 24 h, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
Sigma Aldrich) was added at a concentration of 0.8mgml 1 in DMEM, and the
cells were incubated for additional 4 h. The cells were dissolved in dimethyl sulf-
oxide (Sigma-Aldrich). MTT conversion was determined by measurement of the
A600. Measured absorptions in the IFN wells (Abs) were normalized as a percent of
the cell control (CC) with the virus control (VC) subtracted, using the following
equation: normalized cell survival (NCS)¼ (AbsVC/(CCVC)) 100 to allow
activity comparisons between plates. EC50, efﬁcacy and exponential slope values
were estimated as described in the section entitled ‘Activity assay in HEK293 cells’.
Liver biopsies. Liver biopsies from patients (n¼ 104) were obtained in the out-
patient clinic of the Division of Gastroenterology and Hepatology, University
Hospital Basel, Switzerland. Parts of the biopsy material that were not needed
for routine histopathology were used for research purposes after obtaining
written informed consent. The use of biopsy material for this project was approved
by the Ethikkommission Nordwest- und Zentralschweiz, Basel, Switzerland.
Serum HCV RNA was quantiﬁed using the Cobas AmpliPrep/COBAS TaqMan
HCV Test and the Cobas Amplicor Monitor from Roche Molecular Systems
(Basel, Switzerland).
Total RNA and genomic DNA were isolated from liver biopsies using Trizol
reagent (Invitrogen, Basel, Switzerland) and DNeasy Blood & Tissue Kit (Qiagen,
Hombrechtikon, Switzerland) according to the manufacturer’s instructions. A
fragment of 850 base pair covering rs368234815 and rs117648444 was ampliﬁed
with the Expand High Fidelity PCR System (Roche) using forward 50-ACTGTGTG
TGCTGTGCCTTC-30 and reverse 50-GGACGAGAGGGCGTTAGAG-30 primers.
The product was puriﬁed on a column using NucleoSpin Gel and PCR clean-up
(Macherey-Nagel AG, Oensingen, Switzerland) according to the manufacturer’s
instructions and then sequenced (Microsynth AG, Balgach, Switzerland).
pSVR was calculated using the 4-classiﬁer genes as described previously10.
Statistical analysis was performed using Prism6 (GraphPad software. La Jolla,
CA, USA).
Genetic association study. Samples from patients with written informed consent
for genetic studies and available DNA were collected from the Swiss Hepatitis C
Cohort Study (SCCS), a multicenter study of HCV-infected patients enroled at
eight major Swiss hospitals and their local afﬁliated centres, as described pre-
viously16,34, and from the Liver Unit of the Casa Sollievo della Sofferenza, San
Giovanni Rotondo, Italy. The study was approved by the Ethics Committee of each
SCCS center (Ethikkommission beider Basel EKBB (Basel), Ethikkommission des
Kantons St Gallen (St Gallen), Comite´ intercantonal d’e´thique (Neuchaˆtel), Comite´
d’e´thique du de´partement de Me´decine (Geneva), Department Innere Medizin
Ethisches Komitee (Zurich), Commission d’e´thique de la recherche clinique
(Lausanne), Comitato etico cantonale (Lugano)) and by the Ethical committee of
‘Casa Sollievo della Sofferenza’. The study included Caucasian patients with
spontaneous HCV clearance (deﬁned as presence of anti-HCV antibodies but
undetectable HCV RNA without previous antiviral treatment) and those who had
chronic infection with HCV genotypes 1, 2, 3 or 4 and were assessable for response
to therapy with pegIFNa and ribavirin, that is, who received 480% of the
recommended dose of each drug. Polymorphisms in the IFNL3/4 region
(rs12979860, rs368234815, rs117648444 and rs8099917) were extracted from
a GWAS-generated data set4 or genotyped by TaqMan (Applied Biosystems,
Rotkreuz, Switzerland) or by the Competitive Allele Speciﬁc PCR (KASP)
system (LGC Genomics, Herts, UK; http://www.lgcgenomics.com/kaspchallenge).
Haplotypes were inferred using PHASE software, version 2.1 (University of
Washington, available through Express Licensing Program, Seattle, WA, USA;
http://stephenslab.uchicago.edu/software.html). Statistical analyses were performed
using Stata (version 13.1, StataCorp LP, College Station, TX, USA). LD was
assessed using the programs PWLD implemented in Stata. The association of
polymorphisms with response to treatment and spontaneous clearance was
performed by univariate and multivariate logistic regression. The multivariate
models for spontaneous clearance are adjusted for age, sex and HCV risk. The
multivariate models for response to treatment are adjusted age, sex, ﬁbrosis stage
and viral genotype.
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